LOGIN  |  REGISTER
Viking Therapeutics
C4 Therapeutics

Brookdale Senior Living Reports May 2024 Occupancy

June 10, 2024 | Last Trade: US$6.24 0.07 -1.11

NASHVILLE, Tenn., June 10, 2024 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) reported today its consolidated occupancy for May 2024.

May 2024 Observations

  • Sequentially, May weighted average occupancy increased 20 basis points while month end occupancy increased 30 basis points, supported by ongoing improvement in resident retention.
  • May weighted average occupancy reflected a continued outperformance versus pre-pandemic normal seasonality and represented the Company's thirty-first consecutive month of year-over-year weighted average occupancy growth.
  • Second quarter-to-date weighted average occupancy increased 160 basis points to 78.0% compared to 76.4% for the comparable period of 2023.

About Brookdale Senior Living

Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. The Company is committed to its mission of enriching the lives of the people it serves with compassion, respect, excellence, and integrity. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities. Through its comprehensive network, Brookdale helps to provide seniors with care, connection, and services in an environment that feels like home. The Company's expertise in healthcare, hospitality, and real estate provides residents with opportunities to improve wellness, pursue passions, make new friends, and stay connected with loved ones. Brookdale, through its affiliates, operates and manages 652 communities in 41 states as of March 31, 2024, with the ability to serve approximately 59,000 residents. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit brookdale.com or connect with Brookdale on Facebook or YouTube.

 
Recursion

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page